Denali Therapeutics Inc. $DNLI Stock: VIRGINIA RETIREMENT SYSTEMS ET Al Grows Stake

VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 237.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,300 shares of the company’s stock after buying an additional 34,000 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Denali Therapeutics were worth $998,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DNLI. BlackRock Inc. bought a new stake in shares of Denali Therapeutics in the 2nd quarter valued at about $360,759,000. Dimensional Fund Advisors LP increased its position in shares of Denali Therapeutics by 13.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company’s stock worth $51,687,000 after purchasing an additional 317,872 shares in the last quarter. ADAR1 Capital Management LLC increased its position in shares of Denali Therapeutics by 3,490.9% during the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock worth $35,932,000 after purchasing an additional 1,819,339 shares in the last quarter. Defilade Capital Management L.P. boosted its position in shares of Denali Therapeutics by 107.1% in the 1st quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company’s stock worth $26,111,000 after purchasing an additional 703,256 shares in the last quarter. Finally, Bank of America Corp DE purchased a new position in Denali Therapeutics during the 2nd quarter worth $31,660,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Down 5.9%

NASDAQ DNLI opened at $19.72 on Friday. The business has a fifty day moving average price of $20.25 and a 200 day moving average price of $21.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.21 and a quick ratio of 8.32. Denali Therapeutics Inc. has a one year low of $13.75 and a one year high of $27.30.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Tuesday, November 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.64. The business had revenue of $17.78 million for the quarter, compared to analyst estimates of $12.67 million. During the same period last year, the firm earned ($0.74) EPS. On average, equities research analysts forecast that Denali Therapeutics Inc. will post -2.70 EPS for the current fiscal year.

Key Headlines Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: Denali reported Q3 revenue of $17.78 million, above the $12.67 million consensus, and EPS of $0.37 versus analysts’ expected loss of $0.27. Avlayah sales rose nearly fivefold, reimbursement coverage expanded, and the company cited upcoming pipeline catalysts—factors supporting the reported post-earnings rally. Article: DNLI Up 7.8% Post Q3 Earnings
• Positive Sentiment: Morgan Stanley raised its price target to $42 and maintained an overweight rating; Wedbush raised its target to $24 and reiterated outperform. BTIG also reaffirmed its buy rating with a $39 target, reinforcing favorable analyst sentiment. Morgan Stanley rating information Wedbush rating information BTIG rating information
• Neutral Sentiment: HC Wainwright’s quarterly forecasts project ongoing losses in 2027, ranging from $0.60 per share in Q1 to $0.53 in Q4. These are analyst estimates, not company guidance; the current-year consensus cited in the reports is a loss of $2.70 per share. MarketBeat Denali coverage

Insider Buying and Selling at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,857 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider directly owned 281,763 shares in the company, valued at approximately $7,063,798.41. The trade was a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 9.70% of the company’s stock.

Wall Street Analyst Weigh In

DNLI has been the topic of a number of research analyst reports. Wedbush boosted their price target on Denali Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a research note on Wednesday. B. Riley Financial boosted their price objective on Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Morgan Stanley increased their target price on shares of Denali Therapeutics from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Wednesday. JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a report on Monday, July 13th. They issued an “overweight” rating and a $29.00 price objective on the stock. Finally, UBS Group lifted their price target on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $36.15.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.